In Mitochondrial myopathy, the mitochondria are affected which leads to symptoms such as muscle weakness, muscle cramping, low immunity, poor balance, and fatigue. Mitochondrial myopathy interferes with the functioning of the muscles and might also affect the functioning of other organs. At present, there is no curative therapy for mitochondrial myopathy. As per the analysis of Market Research Future (MRFR), the global mitochondrial myopathy market is expected to exhibit an upswing and attain USD 33.6 Mn at a CAGR of 9.82% by the end of the forecast period of 2017-2020.

Get Free Sample Copy @ www.marketresearchfuture.com/sample_request/3950

Segmentation

The global mitochondrial myopathy diagnosis & treatment market has been segmented based on type, diagnostic tests, and therapy.

By type, the global mitochondrial myopathy diagnosis & treatment market has been segmented into neuropathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), Pearson syndrome, Leigh syndrome, ataxia, mitochondrial DNA depletion syndrome (MDS), Retinitis pigmentosa (NARP), Kearns–Sayre syndrome (KSS), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). The MELAS is the largest segment and is foreseen to capture a CAGR of 19.39% during 2017-2020.

By diagnostic test, the global mitochondrial myopathy diagnosis & treatment market has been segmented into genetic tests, muscle biopsy, and biochemical test. The genetic tests segment was the largest segment in 2016 and is projected to grow at a CAGR of 10.11% over the forecast period.

By therapy, the global mitochondrial myopathy diagnosis & treatment market has been segmented into supportive therapy and targeted therapy. The supportive therapy segment held the largest market share in 2016 and is projected to capture a CAGR of 9.82% over the forecast period.

Browse Complete Report @ Click Here